PT-141 certificate of analysis explained: what to check

Last updated 2026-07-24

What is a certificate of analysis, exactly?

A certificate of analysis, usually shortened to COA, is a document a lab produces after testing a specific batch (a "lot") of a substance. For a peptide like PT-141, a proper COA states the lot number, the test date, the methods used, and the results: purity percentage, identity confirmation, and sometimes checks for residual solvents, heavy metals, or bacterial endotoxin. Think of it as a snapshot of one batch, not a guarantee about every vial that will ever carry that label. A COA from March doesn't tell you anything about a batch made in September. If a seller shows you one PDF and reuses it across months of restocked inventory, that's a red flag, not reassurance. None of this is unique to PT-141. It's standard practice across the research chemical and compounding supply chain. The problem is that a COA on its own proves a lab tested something, not that the something is safe, legal to use the way you plan to use it, or equivalent to an approved drug. For context on what the actual approved version of this molecule is, see pt 141 peptide.

What should a legitimate PT-141 COA actually show?

A COA worth trusting includes, at minimum: the exact compound name (bremelanotide acetate, more than "PT-141"), a batch or lot number, the testing lab's name and location, the method used (usually HPLC for purity, mass spectrometry for identity confirmation), the purity result as a percentage, and a test date. Many research suppliers report purity above 98%. That number alone tells you very little without knowing the method. HPLC (high-performance liquid chromatography) measures how much of the sample is the target molecule versus breakdown products or synthesis byproducts. Mass spec confirms the molecule's identity by weight, which catches cases where a compound resembles the target peptide chemically but isn't quite right. A COA that lists only "purity: 99%" with no method, no lab name, and no lot number is functionally worthless. It's a claim, not a test result. You have no way to verify it came from an accredited lab or that it corresponds to the vial in front of you. Endotoxin testing matters more than most buyers realize, especially for anything injected. Bacterial endotoxins can survive processes that kill the bacteria themselves, and they can cause fever, chills, or more serious reactions even in sterile-looking solution. A COA that skips this test isn't automatically fraudulent, but its absence is worth noticing.

Does a COA mean PT-141 is FDA-approved or safe to use?

No. A certificate of analysis is a chemistry report, not a regulatory approval. The only FDA-approved form of this molecule is Vyleesi, bremelanotide 1.75 mg in a single-dose autoinjector, approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) ^[1]. That approval came after two randomized, placebo-controlled Phase 3 trials (the RECONNECT studies) in premenopausal women with HSDD, which established both a dosing protocol and a documented safety and efficacy profile reviewed by FDA ^[2]. A subgroup analysis of those same RECONNECT trials looked at whether response varied by age, HSDD subtype, and other patient factors ^[3]. Compounded or "research-grade" bremelanotide sold outside that approval pathway has not gone through this review. A vial with a clean-looking COA can still be an unapproved drug product being marketed for uses the FDA has not evaluated. The FDA's own bulk drug substance rules distinguish between substances on the approved 503A and 503B compounding lists and materials sold under research-use-only labeling with no such standing ^[4][5]. Bremelanotide's regulatory status as a compounding bulk substance is governed by these rules, and labeling a product "not for human consumption" while marketing it for sexual desire changes nothing about the product itself; it only changes what the seller is willing to put on the label. Under FDA's own regulations, intended use is judged by how a product is actually marketed, more than by a disclaimer printed on it ^[6]. A drug information summary from The Medical Letter reviewed Vyleesi's approval and dosing details specifically in the context of the approved product, not compounded analogs ^[7].

Why does PT-141 work centrally instead of like sildenafil?

This is the single most useful thing to understand before looking at any lab paperwork. Bremelanotide is a melanocortin receptor agonist. It acts in the brain, primarily through melanocortin 4 receptors (MC4R), to influence sexual desire pathways in the central nervous system ^[8]. Sildenafil (Viagra) and similar drugs work on blood vessels: they relax smooth muscle to increase blood flow to genital tissue. That's a vascular, peripheral mechanism. Bremelanotide's mechanism is upstream of that. It doesn't act on blood flow directly; it acts on desire and arousal circuitry in the brain ^[8][9]. A 2022 review in CNS Spectrums specifically walked through the neurobiology behind this: bremelanotide's action on central melanocortin pathways is why it is studied for desire disorders rather than for erectile or genital blood flow problems ^[8]. This is also why bremelanotide doesn't require sexual stimulation to "work" the way a vascular drug's mechanism implies, and why its side effect pattern (nausea, flushing, headache) looks different from a vasodilator's side effect pattern. Broader review articles on the melanocortin system describe its role across metabolic and inflammatory pathways too, which is part of why researchers are also looking at related molecules for body weight regulation ^[10][11]. That is a separate research question from HSDD treatment, and the two shouldn't be conflated when reading a COA or a marketing claim.

What do the actual efficacy numbers look like?

The two Phase 3 RECONNECT trials tested bremelanotide 1.75 mg subcutaneous, self-administered as needed, in premenopausal women with HSDD ^[2]. Improvements were measured using validated instruments: the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13, which measures distress about low desire. The effect sizes reported were modest. This point matters enough that it has its own literature: a 2024 analysis in the Journal of Sex Research argued the clinical trial effects were small relative to placebo and questioned how meaningfully they translate to patient-reported outcomes ^[12]. A separate 2021 re-analysis in the same journal raised similar concerns about how HSDD itself was defined and measured across the trials . A Drug and Therapeutics Bulletin analysis compared bremelanotide's approval to flibanserin's (Addyi, the earlier FDA-approved HSDD drug) and argued that regulatory precedent, not necessarily strong independent evidence, shaped both approvals ^[13]. This is a legitimate scientific debate, not a fringe objection, and a reader should know it exists before deciding whether an approved product, let alone an unregulated compounded one, is worth pursuing. A Phase 2b dose-ranging study looked at "responder" rates, meaning the proportion of women who reported a clinically meaningful improvement rather than just a statistical average shift, which is often a more intuitive number for patients weighing a decision .

What side effects show up in the trial data?

Nausea is the most common side effect and it is not rare. Across the clinical development program, a dedicated safety analysis found nausea occurred in a substantial share of patients, more often after the first dose and typically declining with repeat use ^[14]. Flushing is the second most common effect. Headache and injection site reactions also appear in trial reporting ^[14][9]. These aren't minor footnote effects; they are common enough that anyone considering bremelanotide, approved or otherwise, should expect to feel some nausea, especially with the first injection. A pharmacotherapy review in The Annals of Pharmacotherapy covering the drug's approval specifically flags nausea as a dose-limiting concern that shaped the approved 1.75 mg dose ^[4]. Blood pressure needs attention too. Bremelanotide can cause a transient increase in blood pressure, which is why the approved label restricts use in patients with uncontrolled hypertension or known cardiovascular disease, and a 2022 review specifically addressed how to manage HSDD treatment decisions in women who also have hypertension . For the fuller breakdown of frequency and severity, see pt 141 peptide side effects. A COA cannot tell you anything about how your body will respond to any of this; that's clinical information, not chemistry.

How is PT-141 actually dosed in the approved product?

Vyleesi is dosed at 1.75 mg per autoinjector, self-injected subcutaneously in the abdomen or thigh, taken as needed at least 45 minutes before anticipated sexual activity, with a maximum of one dose in 24 hours and no more than 8 doses per month per the approved labeling reviewed in trial and pharmacology literature ^[2][4]. This dosing schedule came directly out of the Phase 2b dose-ranging work that tested multiple dose levels before settling on 1.75 mg as the balance point between response rate and tolerability, particularly nausea . Higher doses tested earlier in development produced more nausea without proportionally better response. Compounded and research-labeled PT-141 products are frequently sold in different concentrations, vial sizes, and reconstitution instructions with no equivalent dose-finding study behind the specific product you're holding. A COA showing 99% purity says nothing about whether the concentration on the label matches what's actually in the vial, and concentration accuracy is a separate lab question from purity. For exact numbers and how they compare across formats, see pt-141 dosage chart and use the pt-141 dosage calculator before assuming any two products are equivalent. Guidance on injection technique and timing is covered in pt-141 peptide how to use.

Why does compounded PT-141 exist outside the FDA-approved product?

Compounding pharmacies can legally prepare drug products from bulk substances under 21 U.S.C. 353a, provided they meet specific conditions tied to a patient prescription and substances on FDA's permitted lists ^[15]. FDA maintains separate bulk drug substance lists for 503A pharmacies and 503B outsourcing facilities ^[4][5], and bremelanotide's status on these lists determines whether a compounding pharmacy can legally use it at all. This is different from research-use-only PT-141 sold online with no prescription requirement and no pharmacy oversight, which is the category most COA questions actually come from. A 2020 review of the FDA's 2019 approvals of peptide and oligonucleotide drugs (the "TIDES harvest") placed bremelanotide's approval in the context of a broader wave of peptide therapeutics reaching market that year , which is useful background on why peptide drugs like this one are having a moment in both legitimate and gray-market channels simultaneously. If you want a legitimately sourced version of this compound, the practical path is a provider-reviewed prescription route rather than an unregulated vial with a PDF attached. Bremelanotide Rx works from the position that a provider-reviewed prescription pathway, filled through a licensed pharmacy partner, is the version of this decision that actually has oversight behind it, as opposed to a COA from an unnamed lab.

What does a fake or misleading COA look like in practice?

Warning signs include: no lot number, or the same lot number appearing across months of restocked product; a lab name you cannot independently verify or that doesn't appear in any accreditation registry; purity listed without a testing method; a COA image that is clearly a template with the compound name swapped in; and a COA date that predates the product's stated manufacture date. Another common pattern is a COA for the raw bremelanotide powder, tested by the original chemical manufacturer, being presented as though it certifies the final reconstituted or packaged product a consumer receives. A lot of steps happen between raw powder and a filled vial: reconstitution accuracy, sterility of the final fill, storage conditions, and packaging integrity. None of those downstream steps are covered by a powder-stage COA, even a genuine one. Sellers sometimes list "third-party tested" without naming the third party at all. If you cannot find the lab's name, its location, or any way to contact it, treat the document as unverifiable regardless of how professional the PDF looks.

How do compounded PT-141 sources compare to the FDA-approved product?

Should you buy PT-141 based on a COA alone?

No. A COA is one piece of evidence about one batch of raw material or product. It is not a substitute for a prescriber's evaluation, and it says nothing about whether the specific vial in front of you was made under sanitary conditions, filled at the labeled concentration, or stored correctly during shipping. If you're seriously considering bremelanotide for low sexual desire, the more useful question isn't "does this COA look legitimate" but "am I getting this through a route that has any oversight at all." A provider-reviewed prescription, filled through a licensed pharmacy, means someone has actually screened you for the contraindications that matter (uncontrolled hypertension, cardiovascular disease) and that the dose you're getting matches what was tested in the RECONNECT trials ^[2]. Bremelanotide Rx's own position on this is straightforward: we don't compound or manufacture anything ourselves, and we point readers toward a provider-reviewed pathway filled through a licensed pharmacy partner rather than unregulated vials sold on the promise of a lab report. That's a meaningfully different starting point than trying to evaluate a stranger's COA screenshot.

Frequently asked questions

What is a certificate of analysis for PT-141?

It's a lab document showing test results for a specific batch of the compound: identity confirmation, purity percentage, and often contaminant screening. A complete one names the lab, the test method (HPLC, mass spec), the lot number, and the test date. It covers one batch only, not every vial sold under that label.

Does a COA prove PT-141 is FDA-approved?

No. A COA is a chemistry report, not a regulatory approval. The only FDA-approved bremelanotide product is Vyleesi, approved in 2019 for premenopausal women with hypoactive sexual desire disorder after Phase 3 trials ^[1][11]. Compounded or research-labeled PT-141 with a COA attached has not gone through that same review.

How is PT-141's mechanism different from Viagra or sildenafil?

Bremelanotide works centrally, acting on melanocortin 4 receptors in the brain to influence desire pathways ^[18]. Sildenafil works peripherally, on blood vessels, to increase genital blood flow. Because the mechanisms differ, the side effect profiles differ too: bremelanotide causes nausea and flushing rather than the vascular effects typical of PDE5 inhibitors.

What purity percentage should a legitimate PT-141 COA show?

Many legitimate research suppliers report purity above 98%, tested by HPLC. The number alone means little without a stated method and lab name attached. A COA listing only a percentage with no method, lab, or lot number is not verifiable and shouldn't be trusted as evidence of quality.

What are the most common PT-141 side effects reported in trials?

Nausea is the most common, especially after the first dose, followed by flushing, headache, and injection site reactions ^[4][6]. A dedicated safety review across the full clinical development program documented these patterns and found nausea often lessens with repeated use rather than staying constant ^[4].

Can PT-141 raise blood pressure?

Yes, transiently. This is why the approved product's labeling restricts use in people with uncontrolled hypertension or cardiovascular disease, and a 2022 clinical review specifically addressed managing HSDD treatment decisions in women who also have high blood pressure ^[22]. Anyone with cardiovascular risk factors should be screened by a prescriber before use.

Is compounded PT-141 legal to buy?

It depends on how it's sold and marketed. Compounding pharmacies can legally prepare products from bulk substances under specific FDA rules tied to a prescription ^[8][9][10]. Products sold as "research use only" without a prescription and marketed for human sexual use may fall outside those protections, regardless of disclaimers on the label ^[7].

Why does the FDA-approved dose differ from what some sellers list?

Vyleesi's 1.75 mg dose came from Phase 2b dose-ranging trials that tested multiple concentrations before identifying the balance point between response and tolerability, mainly nausea ^[21]. Compounded products sold at other concentrations have generally not gone through an equivalent dose-finding study specific to that formulation.

How effective is PT-141 according to the actual trial data?

The RECONNECT Phase 3 trials showed statistically significant but modest improvements in desire scores and distress measures versus placebo ^[11]. Independent re-analyses have argued the clinical effect sizes are small and questioned how meaningfully they translate into patient experience ^[20][23], so expectations should be realistic rather than dramatic.

Does a third-party lab test guarantee sterility?

No. Purity and identity testing (HPLC, mass spec) says nothing about sterility or endotoxin levels unless those specific tests are listed separately on the COA. Endotoxin testing matters especially for injectable products, since bacterial endotoxins can cause fever or reactions even after bacteria are killed.

What's the difference between raw powder testing and final product testing?

A COA for raw bremelanotide powder, tested at the manufacturing stage, does not cover what happens afterward: reconstitution accuracy, sterile fill, packaging, and storage. A powder-stage COA being presented as certification for a finished consumer vial is a common misleading practice worth watching for.

Who is PT-141 (Vyleesi) actually approved for?

Vyleesi is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), meaning desire loss that developed after previously normal desire and applies across situations rather than one specific partner or context ^[1][2]. It is not approved for men or for postmenopausal women.

Where should I actually get PT-141 if I want it legitimately?

A provider-reviewed prescription filled through a licensed pharmacy is the route with actual oversight: screening for contraindications like uncontrolled hypertension, confirmation of dose accuracy, and accountability if something goes wrong. Bremelanotide Rx points readers toward that pathway rather than unregulated vials sold with a standalone lab report.

Sources

1. PubMed, Bremelanotide: First Approval (Drugs, 2019): Bremelanotide was FDA-approved as Vyleesi in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder
2. PubMed, Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment (Journal of Midwifery & Women's Health, 2021): Defines HSDD as acquired, generalized loss of sexual desire and describes assessment and diagnosis criteria
3. PubMed, Safety Profile of Bremelanotide Across the Clinical Development Program (Journal of Women's Health, 2022): Nausea and flushing are the most commonly reported side effects across the bremelanotide clinical development program, with nausea often declining after first dose
4. PubMed, Targeting the central melanocortin system for the treatment of metabolic disorders (Nature Reviews Endocrinology, 2023): Describes the central melanocortin system's broader role in metabolic regulation, separate from its role in sexual desire
5. PubMed, Bremelanotide for Treatment of Female Hypoactive Sexual Desire (Neurology International, 2022): Reviews bremelanotide's central mechanism of action and its documented side effect pattern including headache and injection site reactions
6. eCFR, 21 CFR 201.128, Meaning of Intended Uses: A product's intended use, and thus its regulatory status, is determined by how it is marketed and represented, not solely by disclaimer language on its label
7. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA maintains a specific list governing which bulk drug substances 503A compounding pharmacies may legally use
8. eCFR, 21 CFR 216.24, the 503B Bulks List: A separate bulk drug substance list applies to 503B outsourcing facilities, distinct from the 503A list
9. Cornell Law School, Legal Information Institute, 21 U.S.C. 353a: Compounding pharmacies may legally prepare drug products from bulk substances only under specific conditions tied to a valid prescription and permitted substance lists
10. PubMed, Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (Obstetrics and Gynecology, 2019): The RECONNECT Phase 3 trials tested bremelanotide 1.75 mg subcutaneous in premenopausal women with HSDD and established the approved dosing protocol and efficacy data
11. PubMed, Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide (Journal of Women's Health, 2022): Subgroup analyses of the RECONNECT trials examined whether treatment response varied by age and HSDD subtype
12. PubMed, Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent (Drug and Therapeutics Bulletin, 2021): Analysis argues that regulatory precedent, rather than strong independent efficacy evidence, influenced the approval pathway for both bremelanotide and flibanserin
13. PubMed, Bremelanotide (Vyleesi) for hypoactive sexual desire disorder (The Medical Letter on Drugs and Therapeutics, 2019): Independent drug information review summarizing Vyleesi's approved dosing and clinical trial basis
14. PubMed, The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women (CNS Spectrums, 2022): Bremelanotide acts centrally via melanocortin 4 receptors in the brain to influence sexual desire pathways, distinct from peripheral vascular drug mechanisms
15. PubMed, Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin (Biomolecules, 2022): Reviews the broader family of melanocortin receptor ligands and their range of physiological roles beyond sexual function
16. PubMed, Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder (Journal of Sex Research, 2024): Analysis argues that bremelanotide's clinical trial effect sizes versus placebo were small and questions their clinical meaningfulness
17. PubMed, Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide (The Journal of Sexual Medicine, 2019): Phase 2b dose-ranging study identified 1.75 mg as the dose balancing response rate against nausea and tolerability, forming the basis for the approved dose
18. PubMed, Management of Hypertension with Female Sexual Dysfunction (Medicina, 2022): Reviews clinical management considerations for treating HSDD in women who also have hypertension, given bremelanotide's transient blood pressure effects
19. PubMed, Re-Analyzing Phase III Bremelanotide Trials for HSDD in Women (Journal of Sex Research, 2021): Independent re-analysis raised concerns about how HSDD was defined and measured across the Phase 3 bremelanotide trials
20. PubMed, 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest (Pharmaceuticals, 2020): Places bremelanotide's 2019 approval within the broader context of that year's wave of FDA-approved peptide and oligonucleotide drugs